MedTrace Logo

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

NCT04933825 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-02-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.

Conditions

  • Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Interventions

BIOLOGICAL

ET-02

A conditioning therapy with cyclophosphamide and fludarabine will be conducted before ET-02 injection.

Sponsors & Collaborators

  • The First Affiliated Hospital of Henan University of Science and Technology

    collaborator OTHER

  • EdiGene (GuangZhou) Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-20
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04933825 on ClinicalTrials.gov